Portal de Periódicos da CAPES

Rectal bismuth subsalicylate as therapy for ulcerative colitis

1990; Wiley; Volume: 4; Issue: 4 Linguagem: Inglês

10.1111/j.1365-2036.1990.tb00480.x

1365-2036

Stephen Ryder, R J Walker, H W Jones, Jonathan M. Rhodes,

Autoimmune and Inflammatory Disorders

SUMMARY In a prospective open study, 15 patients with ulcerative colitis which was unresponsive to conventional therapy were treated with enemas containing bismuth subsalicylate (700 or 800 mg b.d.). Nine out of the 15 patients showed a significant clinical response, and 6 had gone into complete clinical remission after 8 weeks. treatment. Sigmoidoscopic appearances of the rectal mucosa showed improvement in 9 out of 15 patients at 2 weeks, and 11 out of 15 at 8 weeks. The mucosa appeared sigmoidoscopically normal in 6 out of 15 at 8 weeks. It proved possible to reduce the oral prednisolone dosage from a median of 15 mg/day (range 10 to 35 mg/day) to 6 mg/day (range 0 to 18 mg/day) after 8 weeks of treatment; 5 patients were no longer taking oral steroids at this time. Rectal bismuth subsalicylate appears likely to be an effective therapy in ulcerative colitis and controlled trials are now required.